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Abstract
Tyrosine phosphorylation can modulate GABA A receptor function, and deletion of the fyn kinase gene alters GABAergic function in olfactory bulb neurons (Kitazawa et al., 1998) . Our goal was to determine whether fyn gene deletion altered behavioral and functional actions of compounds that act on GABA A receptors. Such evidence might suggest a role for fyn-kinase in modulating GABA A receptor function, possibly via direct interactions between the kinase and receptor. Using the loss of righting reflex test, we found that null mutants were less sensitive to the hypnotic effects of THIP, a GABA A receptor agonist. Subunit specificity was suggested by the observation that null mutants were also less sensitive to the hypnotic effects of etomidate, a GABAergic compound that is selective for receptors possessing β 2 and/or β 3 receptor subunits. The genotypes did not differ in sensitivity to zolpidem, an α 1-selective GABAergic drug. GABA A receptor functional assays ( 36 Cl -influx) supported our behavioral results; the actions of the GABA A agonists, THIP and muscimol, were reduced in the cerebellar membranes of fyn null mutant mice. Importantly, similar results were seen with etomidate. Binding of 3 Hflunitrazepam supported the idea that this is due to a decrease in functional GABA A receptor density. These data suggest that fyn-kinase may alter the function of GABA A receptors, perhaps via actions on β 2 and/or β 3 receptor subunits.
Fyn-kinase, a member of the src family of non-receptor tyrosine kinases, is localized at the growth cones and post-synaptic membranes of neurons and can be found in a number of brain regions including the olfactory bulb, cerebellum, hippocampus, and limbic system (Yagi et al., 1993) . Studies have shown that fyn-kinase phosphorylates the NMDA receptor (Suzuki and Okumura-Noji, 1995; Yaka et al., 2003) , modulating its function. Indeed, Miyakawa and colleagues (1997) demonstrated that fyn phosphorylation of the NR2B subunit is necessary for the development of acute tolerance to alcohol's inhibitory effects on NMDA receptor-mediated currents in hippocampal neurons. These authors argued that this process explained the enhanced sensitivity to the hypnotic effects of alcohol seen in fyn-deficient mice; because fyn-kinase is not available to phosphorylate the NR2B subunit, these mice cannot develop acute tolerance to alcohol.
However, fyn-kinase may also phosphorylate the GABA A receptor, and this receptor system is known to modulate ethanol's hypnotic effects . One study showed that granule cells in the olfactory bulb of fyn deficient mice exhibit reduced sensitivity to bicuculline and picrotoxin, antagonists at the GABA A receptor (Kitazawa et al., 1998) . Moreover, several studies have shown that src tyrosine kinase, closely related to fyn-kinase, interacts with or phosphorylates the γ2 (Brandon et al., 2001; Valenzuela et al., 1995) and β (Brandon et al., 2001; Valenzuela et al., 1995; Wan et al., 1997) subunits of the GABA A receptor. Thus, the available evidence suggests that deletion of the fynkinase gene may, in addition to the NMDA receptor, interact with the GABA A receptor.
The present studies examined the potential interaction between fyn-kinase and GABA A receptors in fyn null mutant and wild-type mice. We assessed hypnotic sensitivity to the GABA A receptor agonist, tetrahydroisoxazolo [5,4-c] 
Materials and Methods
Animals. Fyn-kinase null mutant (B6;129S-Fyn tm1Sor ) and control mice (B6129SF2/J) were obtained from Jackson Laboratories (Bar Harbor, ME), and bred to generate the mice used in the present studies. These mice were originally developed by Stein et al. (1992) . Heterozygote mating pairs were maintained to produce wild-type, heterozygous, and homozygous littermates. To minimize the possible effect of genetic background, littermates were used in the present studies. For most experiments, both
male and female mice were tested. However, due to availability only female mice were tested in several experiments. Mice were housed in same-sex groups, four to five to a cage. Food and water were available ad libitum. The vivarium was maintained on a 12:12-hr light/dark cycle with lights on at 7:00 AM. The temperature and humidity of the room were maintained at 20°C and 50%, respectively. All experiments were performed during the light phase of the light/dark cycle. Behavioral testing began when the mice were at least three months and not more than six months old.
Drugs. THIP and alfaxalone were obtained from Sigma (St. Louis, MO).
Flurazepam and diazepam were purchased from Hoffman-LaRoche (Nutley, NJ), pentobarbital from Sigma/RBI (Natick, MA), etomidate from Tocris (Ellisville, MO).
Zolpidem was a generous gift from Dr. J.S. Vedo (Pharmacia, Skokie, IL). For behavioral experiments, THIP and pentobarbital were dissolved in 0.9% saline (20 % v/v Because regain of the righting reflex is measured at long intervals (in some cases as long as several hrs) following drug administration, it is possible that acute tolerance, and not sensitivity per se, can produce genotypic differences. Thus, we assessed initial sensitivity to etomidate-induced loss of righting reflex using the up and down method described by Dixon (1965) . Each mouse was injected with a given drug dose, and placed in the v-shaped troughs used above. For this test, loss of righting reflex was defined as an inability to right for one min within 5 min of drug administration. The hypnotic effect of the given dose determined the drug dose that the next animal received (i.e., if the mouse was unable to right itself then the dose of etomidate was decreased by a log interval, or if the mouse successfully righted itself the etomidate dose was increased by a log interval). 2 µCi/ml of assay buffer: 1 µCi = 37 kBq) containing the drugs to be tested. Three seconds after the addition of 36 Cl -, influx was terminated by adding 4 ml of ice-cold quench buffer (assay buffer with 100 µM picrotoxin) followed by rapid filtration through a GB100R filter (Advantec MFS, Dublin, CA), and subsequent washing with 8 ml quench buffer. Filters were incubated overnight in 4 ml Biosafe II scintillation liquid when agonist was present in the assay medium (total uptake) minus the amount of 36 Cl -uptake when agonist was not present (muscimol-or THIP-independent or non-specific uptake). Etomidate-potentiation of muscimol stimulatedEtomidate concentrations were 1, 3, and 10 µ M. These concentrations were chosen based on a pilot study, and because they are very near the ED 50 for etomidate's anesthetic effects in vivo (Tomlin et al., 1998) . included both males and females did not indicate significant interactions of gender with any other factor. Thus, male and female data were combined for experiments in which both genders were tested. Data are reported as mean ± S.E.M. (except initial sensitivity to loss of righting reflex data which is reported as ED 50 ± 95% confidence interval), and were analyzed using two-tailed t-test or two-way ANOVA. Post-hoc comparisons were made where appropriate.
Results
Loss of righting reflex. To assess whether sensitivity to GABAergic drugs was altered by null mutation of the fyn-kinase gene, duration of loss of righting reflex was measured following administration of THIP (GABA A receptor partial agonist), and the non-subunit selective allosteric modulators pentobarbital, flurazepam, and alfaxalone.
Fyn null mutant mice were less sensitive to the hypnotic effects of THIP as they exhibited a shorter duration of loss of righting reflex compared to their wild-type counterparts ( Figure 1 ). However, the genotypes did not significantly differ in sensitivity to the hypnotic effects of pentobarbital, flurazepam, or alfaxalone (Table 1) .
We next wanted to establish whether the reduced sensitivity to THIP in fyn null mutant mice might be subunit specific. We measured hypnotic sensitivity to the α 1-selective drug, zolpidem, and the β 2/β3-selective drug, etomidate. Fyn null mutant and wild-type mice did not differ in sensitivity to zolpidem (Figure 2A ). However, fyn deficient mice were less sensitive to the hypnotic effects of etomidate ( Figure 2B Fyn deficient mice were less sensitive to muscimol-stimulated 36 Cl -flux in cerebellar microsacs (EC 50 ± 95% confidence interval: 1.2 ± 0.2 and 0.9 ± 0.2 µ M for null mutant and wild-type, respectively; Emax ± SEM: 6.2 ± 0.5 and 8.5 ± 0.6 nmol/mg protein for null mutants and wild-types, respectively; Figure 3B ). However, fyn null mutant and wild-type mice did not differ in sensitivity to muscimol-stimulation of 36 Cl -flux in cortical microsacs (EC 50 ± 95% confidence interval: 8.0 ± 1.1 and 7.3 ± 1.2 µ M for null mutant and wild-type, respectively; Emax ± SEM: 21.5 ± 1.7 and 21.9 ± 2.4 nmols/mg protein for null mutant and wild-type, respectively; Figure 3A ). The actions of etomidate were reduced at concentrations at or below the ED 50 for its anesthetic effects in the cerebellar microsacs of fyn null mutant mice ( Figure 4B ).
However, similar to that seen following muscimol and THIP application, etomidate did not differentially alter muscimol-stimulated chloride flux in cortical microsacs ( Figure   4A ). These results are in agreement with our behavioral data, and strongly implicate the β 2 and/or β 3 receptor subunits in the interaction between fyn-kinase and GABAergic systems. did not differ between the genotypes (6.7 ± 1.9 and 5.3 ± 1.5 nM for null mutants and wild-types, respectively). The cortical binding curves were similar for both genotypes (Kd: 6.8 ± 1.5 and 5.9 ± 1.4 nM for null mutants and wild-types, respectively; B max : 1534 ± 90 and 1414 ± 87 fmol/mg for null mutants and wild-types, respectively).
Discussion
The goal of the present studies was to determine whether fyn gene deletion altered the behavioral and functional actions of drugs that act at GABA A receptors. To this end, we obtained our own colony of fyn null mutant and wild-type mice. Similar to the results of Miyakawa et al. (1997) using mice that were developed by a different research group, our null mutants were more sensitive to the hypnotic effects of ethanol (Boehm II et al., 2003) , a compound known to enhance GABA A receptor function. Moreover, although the genotypes did not differ in hypnotic sensitivity to the positive allosteric modulators pentobarbital, flurazepam, and alfaxalone, our fyn-deficient mice exhibited a shorter duration of loss of righting reflex following administration of the GABA A receptor agonist, THIP.
The above results were consistent with those of Kitazawa et al. (1998) , and suggested that fyn gene deletion altered GABA A receptor function, so we next assessed the actions of THIP using a functional assay. THIP-stimulated 36 Cl -flux was reduced in the cerebellar microsacs of fyn null mutant mice, consistent with their reduced hypnotic sensitivity. Moreover, the actions of another GABA A receptor agonist, muscimol, were also reduced. No such changes were observed in cortical membranes.
Our results suggest that fyn-kinase may phosphorylate GABA A receptors in the cerebellum, altering their function. However, there is currently no direct evidence indicating that fyn interacts with this receptor, or any another protein important for GABAergic function. Indeed, it is possible that the resulting GABA-related phenotypes may have resulted from fyn's absence during neuronal development (Yagi, 1999) ; fyn-kinase is expressed during neuronal cell migration and differentiation, axon guidance, target recognition, and synaptogenesis (Yagi, 1994) .
One way to distinguish between these possibilities is to assess sensitivity to subunit specific drugs. We reasoned that if fyn was necessary for the normal development of GABA A receptor systems, then differences in GABAergic sensitivity observed between fyn-deficient and wild-type mice would likely not exhibit subunit selectivity. We initially chose to assess behavioral sensitivity to two different GABA A receptor drugs, the phosphorylates the GABA A γ2 (Brandon et al., 2001; Valenzuela et al., 1995) and β (Brandon et al., 2001; Valenzuela et al., 1995; Wan et al., 1997) subunits. Studies aimed at determining whether fyn-kinase phosphorylates β 2 and/or β 3 receptor subunits are underway in our laboratory.
Behavioral data suggest that β 3 receptor subunits may be more important targets for fyn than β 2 receptor subunits. β 3 null mutant mice were less sensitive to etomidate and exhibited equal sensitivity to pentobarbital (Quinlan et al., 1998) , and mice in which a point mutation was introduced into the β 3 subunit gene were much less sensitive to the hypnotic effects of etomidate but did not differ in hypnotic sensitivity to alfaxalone (Jurd et al., 2003) . In contrast, mice with the same mutation in the β 2 subunit gene differed in sensitivity to the sedative, but not hypnotic effects of etomidate (Reynolds et al., 2003) , showed that β 2 null mutant mice were less sensitive to the hypnotic effects of flurazepam, THIP, etomidate, and zolpidem, but not pentobarbital.
Thus, our behavioral data are most consistent with that from β 3 mutant mice.
A potential problem in attributing our findings to fyn's actions at β 3 receptor subunits is that muscimol and THIP do not appear to exhibit β subunit specificity.
However, Ebert et al. (1997) reported that muscimol exhibited greater efficacy at α 6-
, and other studies demonstrated that THIP has a greater efficacy than GABA at receptors composed of α 6βxγ2s, that it is a full agonist at receptors composed of α 5βxγ2s, and that it is only a partial agonist at receptors composed of α 1-4βxγ2s (Ebert et al., 1994; Wafford et al., 1996) . Here we report that fyn kinase null mutants were less sensitive to the functional actions of muscimol, and less sensitive to the behavioral and functional actions of THIP. Considered along with evidence that cerebellar GABA A receptors are composed of α 1βxγ2, α 6βxγ2, and α 6βxδ containing receptors (Saxena et al., 1996; Pöltl et al., 2003) , that fyn null mutants do not differ in hypnotic sensitivity to the α 1-selective benzodiazepine, zolpidem (current study), and that 3 H-muscimol labeled cerebellar GABA A receptors are primarily composed of α 6βxδ (Quirk et al., 1994) , we speculate that fyn kinase interacts with β 3-containing GABA A receptors that also possess α 6 and δ subunits. If true, it might explain how sensitivity to compounds that lack β subunit specificity might also have been altered in fyn-kinase null mutant mice; mutated fyn was incapable of phosphorylating receptors composed of these subunits, resulting in the reduced actions of muscimol and THIP.
Interestingly, α 6β3δ containing GABA A receptors were recently implicated as being highly sensitive to the enhancing effects of ethanol (Wallner et al., 2003) .
Despite the reduced number of benzodiazepine ( 3 H-flunitrazepam) binding sites in the cerebellum of fyn null mutant mice, we did not observe changes in hypnotic sensitivity to zolpidem or flurazepam. Although puzzling, the subunit selectivity of these drugs might offer an explanation (Smith, 2001) . For example, zolpidem preferentially binds GABA A receptors that posses α 1 subunits. We hypothesize that fyn-kinase interacts with GABA A receptors that posses α 6, and not α 1 subunits. Therefore, we might not expect to see genotypic differences in hypnotic sensitivity to zolpidem. However, it is currently unknown whether flunitrazepam or flurazepam exhibit any subunit selectivity.
An intriguing finding from our functional studies was that the actions of muscimol, THIP, and etomidate were reduced in cerebellar, but not cortical membranes.
In so far as the righting reflex involves motor control, this finding was not surprising.
Cerebellar nuclei have long been known to mediate motor functions (Miall, 1998) .
Moreover, the available data suggest that etomidate's hypnotic effects are likely mediated by β 3-containing GABA A receptors (Jurd et al., 2003) , and that these subunits are more abundant in cerebellum, compared to cortex (Fritschy and Mohler, 1995) . Nevertheless, β 3 receptor subunits are found in cortex, and it is not clear why we did not detect changes in GABA A receptor function in this brain region. It is interesting to note, however, that we also did not detect genotypic differences in cortical 3 H-flunitrazepam binding.
It is tempting to speculate as to which cerebellar cell types might be important for imparting fyn's effects on GABAergic function. An early paper reported that ethanol depression of Purkinje cell activity correlated with enhanced hypnotic sensitivity to ethanol using the loss of righting reflex test (Johnson et al., 1985) . Indeed, fyn kinase has been localized to cerebellar Purkinje cells (Seykora et al., 2002) , and mRNA coding for β 3 subunits have also been localized to these neurons (Zdilar et al., 1992; Laurie et al., 1992) . However, more recent studies examining protein expression have localized β 3 subunits to cerebellar granule cells, and not Purkinje cells (Fritschy and Mohler, 1995; Pirker et al., 2000) . Thus, the literature is not in agreement on the precise localization of cerebellar β 3 receptor subunits. Nevertheless, as fyn-kinase has also been localized to cerebellar granule cells, it could presumably interact with β 3 subunits to alter GABAergic function in either cell type. A.
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